(S)-3,4-DCPG (UBP1109), mGlu8a agonist (ab120006)
Key features and details
- mGlu8a agonist
- CAS Number: 201730-11-2
- Soluble in water to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
(S)-3,4-DCPG (UBP1109), mGlu8a agonist -
Description
mGlu8a agonist -
Alternative names
- UBP1109
-
Biological description
Potent, selective mGlu8a agonist (EC50 = 31 nM). Displays >100-fold selectivity over mGlu1-7. Systemically active in vivo.
Also available in simple stock solutions (ab146696) - add 1 ml of water to get an exact, ready-to-use concentration. -
CAS Number
201730-11-2 -
Chemical structure
Properties
-
Chemical name
(S)-3,4-Dicarboxyphenylglycine -
Molecular weight
239.18 -
Molecular formula
C10H9NO6 -
PubChem identifier
16062593 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in water to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
OC(=O)c1cc(ccc1C(=O)O)[C@H](N)C(=O)O -
Source
Synthetic
-
Research areas
Images
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (3)
ab120006 has been referenced in 3 publications.
- Gosnell HB et al. mGluR8 modulates excitatory transmission in the bed nucleus of the stria terminalis in a stress-dependent manner. Neuropsychopharmacology 36:1599-607 (2011). PubMed: 21451497
- Beurrier C et al. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 23:3619-28 (2009). PubMed: 19525404
- Lopez S et al. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci 27:6701-11 (2007). PubMed: 17581957